Pharming Group Receives Accelerated Assessment in Europe for leniolisib for the Treatment of Rare Immunodeficiency, APDS
EMA accelerated assessment allows a shorter review period for leniolisib from a standard 210 days to 150 days Pharming is on track to submit its Marketing Authorisation Application for leniolisib in H2 2022 LEIDEN, the Netherlands, Aug. 1, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR)...
Waterdrop Insurance Marketplace Opens Its First Agency Outlet in Wuhan
BEIJING, Aug. 17, 2022 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, recently opened its first agency outlet in Wuhan. It will provide local residents with a range of specialized insurance services, such as insurance customization, security risk assessment, policy...
Innovent Announces First Patient Dosing in Australia in Phase 1 Study of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) in Patients with Advanced Malignancies
ROCKVILLE, Md. and SUZHOU, China, Aug. 23, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announced that the first patient dosing in Australia for its proprietary PD-1/IL-2 bispecific antibody fusion protein (R&D code: IBI363) in...
MGI Wins IBO Design Gold Award for DNBelab C4 Pocket Single-Cell Lab
SHENZHEN, China, Aug. 24, 2022 /PRNewswire/ -- MGI Tech Co. Ltd. (MGI), a global life science leader and innovator, has been awarded Gold by Instrument Business Outlook (IBO) at the 2022 IBO Design Awards for the outstanding design and functionality of its DNBelab C4 Pocket Single-Cell Lab. "MGI is proud to be recognized by IBO for the innovative thinking,...
United Imaging and Carrollton Regional Medical Center Accelerate Installation of the Revolutionary uCT® ATLAS Scanner
Highlights Agility of Both Organizations in Responding to Patient Needs HOUSTON, Sept. 21, 2022 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, announced that it delivered its flagship uCT ATLAS scanner earlier than first scheduled, at the request of Carrollton Regional Medical Center (CRMC). CRMC had placed the order for the...
AAHRPP Accredits Five More Research Organizations, Including First in Japan
WASHINGTON, Sept. 24, 2022 /PRNewswire/ -- The Association for the Accreditation of Human Research Protection Programs has accredited five more research organizations, including its first organization in Japan, two public research universities, a children's hospital and an acute-care hospital. At its September meeting, AAHRPP's Council on Accreditation awarded full accreditation to: ...
Roche introduces the navify brand for its digital health solutions at HLTH 2022
Roche unifies its digital health portfolio under the navify brand, providing a range of next generation software solutions. The navify portfolio uses digital solutions, analytics and data science to provide insights that address today's real-world challenges in health, enabling confident decisions and leading towards delivery of personalised healthcare. The navify digital solutions reinforce Roche's commitment to help...
CBC-backed ABio-X appoints pharmaceutical and healthcare veteran Dr. Jeffrey Jonas as CEO
WALTHAM, Mass., Nov. 10, 2022 /PRNewswire/ -- ABio-X, the Massachusetts-based biotech incubation platform focused on transformative medicines and breakthrough technologies, today announced the appointment of Jeffrey Jonas, M.D., as its Chief Executive Officer (CEO). Dr. Jonas brings with him more than 25 years of experience in drug development and discovery across multiple therapeutic areas in the pharmaceutical and healthcare...
IND approval from the US FDA for theranostic SAR-Bombesin trial in prostate cancer
SYDNEY, Nov. 21, 2022 /PRNewswire/ -- Highlights Clarity's fifth successful Investigational New Drug (IND) application with the United States Food and Drug Administration (US FDA), opening up therapeutic applications for SAR-Bombesin A total of six products with both the diagnostic and therapeutic applications for SARTATE, SAR-bisPSMA and SAR Bombesin are now under IND for US clinical trials First...
Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+,...
ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancers. ESR1 mutations are a known driver of resistance to standard endocrine therapy, and so far, have been difficult to treat. ORSERDU is the first endocrine innovation in more than 20 years, specifically addressing ESR1 mutations,...
